BRIGHAM AND WOMENS HOSPITAL
- Type
- Teaching hospital
- Where
- BOSTON, MA
- Medicare CCN
- 220110
- Received
- $57,962,347 in 1,871 records, 2024 ($8,122,911 general, $49,839,436 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: BRIGHAM & WOMENS HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 264 | $8,122,911 |
| 2024 | Research payment | 1,607 | $49,839,436 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,607 | $49,839,436 |
| Grant | 26 | $2,957,950 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 35 | $2,382,957 |
| Royalty or License | 66 | $1,167,738 |
| Charitable Contribution | 21 | $560,783 |
| Space rental or facility fees (teaching hospital only) | 51 | $438,592 |
| Consulting Fee | 18 | $367,847 |
| Education | 17 | $117,301 |
| Long term medical supply or device loan | 13 | $87,540 |
| Debt forgiveness | 11 | $30,205 |
| Gift | 6 | $11,993 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $145,463 | Research payment | In-kind items and services | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | Cardiac RADIoablation versus repeat catheter Ablation: a pivotalrandomized clinical Trial Evaluating safety and efficacy | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $35,662 | Research payment | In-kind items and services | TIPCAM1 Device, LAPAROSCOPY | Image-guided Lymphadenectomy in AMIGO (Advanced Multimodality Image-Guided Operating) (Augmented Reality Surgical Naviga | 2024 |
| 2024-12-31 | ENDOTRONIX, INC. | $27,251 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $24,081 | Research payment | In-kind items and services | BREZTRI Drug, Respiratory | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $15,431 | Research payment | In-kind items and services | TIPCAM1 Device, LAPAROSCOPY | Image-guided Lymphadenectomy in AMIGO (Advanced Multimodality Image-Guided Operating) (Augmented Reality Surgical Naviga | 2024 |
| 2024-12-31 | Haemonetics Corporation | $9,047 | Research payment | In-kind items and services | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | THROMBOELASTOGRAPHIC PROFILES IN POST-PARTUM HEMORRHAGE | 2024 |
| 2024-12-31 | Cambridge Interventional LLC | $6,000 | Long term medical supply or device loan | In-kind items and services | CRF Device, RFA | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Abbott Laboratories | $2,625 | Research payment | In-kind items and services | ARCHITECT Device, CORE DIAGNOSTICS | Evaluation of Cardiovascular Biomarkers in Patients with Type 2 Diabetes Mellitus at Risk for or with Estiblished Athero | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $2,189 | Research payment | In-kind items and services | TEZSPIRE Biological, Respiratory | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,473 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | ";Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Ev | 2024 |
| 2024-12-31 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF | 2024 | |
| 2024-12-31 | ABBVIE INC. | $749 | Research payment | In-kind items and services | M16-077 Elezanumab Ph 2a POC SCI ELASCI | 2024 | |
| 2024-12-31 | Abbott Laboratories | $700 | Research payment | In-kind items and services | ARCHITECT Device, CORE DIAGNOSTICS | PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $381 | Research payment | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descrip | 2024 |
| 2024-12-31 | Stryker Corporation | $343 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Masimo Corporation | $342 | Long term medical supply or device loan | Cash or cash equivalent | LiDCO Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $342 | Long term medical supply or device loan | Cash or cash equivalent | LiDCO Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $342 | Long term medical supply or device loan | Cash or cash equivalent | LiDCO Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $342 | Long term medical supply or device loan | Cash or cash equivalent | LiDCO Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $342 | Long term medical supply or device loan | Cash or cash equivalent | LiDCO Device, Devices | 2024 | |
| 2024-12-31 | Atos Medical Inc | $93 | Debt forgiveness (3 payments) | Cash or cash equivalent | Provox Life Home HME Device, Tracheostomy | 2024 | |
| 2024-12-30 | InSightec,LTD | $865,678 | Royalty or License | Cash or cash equivalent | EXABLATE Device, NEUROLOGY | 2024 | |
| 2024-12-30 | PFIZER INC. | $508,271 | Research payment | Cash or cash equivalent | A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF | 2024 | |
| 2024-12-30 | ModernaTX, Inc. | $1,625 | Research payment | Cash or cash equivalent | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 | |
| 2024-12-30 | Cleerly, Inc. | $1,580 | Research payment | Cash or cash equivalent | Cleerly Ischemia Device, Cardiology/Vascular Diseases | Confirm2 | 2024 |
| 2024-12-27 | Kowa Holdings America, Inc. | $524 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-26 | Ferring Pharmaceuticals AS | $17,787 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcer | 2024 |
| 2024-12-26 | Ferring Pharmaceuticals AS | $2,700 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcer | 2024 |
| 2024-12-26 | Abbott Laboratories | $2,000 | Consulting Fee | Cash or cash equivalent | XIENCE SKYPOINT Device, Vascular | 2024 | |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $591 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $591 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $45 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $45 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $45 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $45 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-25 | Canon Medical Systems Corporation | $169,745 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-24 | Kowa Holdings America, Inc. | $4,903 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-24 | InSightec,LTD | $1,111 | Research payment | Cash or cash equivalent | Exablate Device, NEUROLOGY | PD006 | 2024 |
| 2024-12-24 | Kowa Holdings America, Inc. | $572 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-23 | SANOFI US SERVICES INC. | $82,818 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-23 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | $43,960 | Research payment | Cash or cash equivalent | Device | SUB-001716 | 2024 |
| 2024-12-23 | Roche Diagnostics Corporation | $21,753 | Research payment | Cash or cash equivalent | Device, None | RD007294: The BREATHE Study: Benefits of Respiratory Evaluation Approaches to Testing on Health Economics | 2024 |
| 2024-12-23 | Medical Device Business Services, Inc. | $4,700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-23 | Janssen Research & Development, LLC | $2,466 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | Prospective evaluation of ustekinumab dose intesification in inflammatory bowel diseases | 2024 |
| 2024-12-23 | Siemens Medical Solutions USA, Inc. | $264 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | Konica Minolta Healthcare Americas, Inc | $90,000 | Research payment | Cash or cash equivalent | Clinical Research Support | 2024 | |
| 2024-12-20 | Apellis Pharmaceuticals, Inc. | $84,702 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | E.R. Squibb & Sons, L.L.C. | $36,712 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | Characterization of scRNAseq profiles associated with ozanimod treatment and age in MS patients | 2024 |
| 2024-12-20 | Blueprint Medicines Corporation | $9,179 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 | |
| 2024-12-20 | Recor Medical Inc | $8,308 | Research payment | Cash or cash equivalent | PARADISE RENAL DENERVATION SYSTEM Device, Nephrology | US GPS | 2024 |
| 2024-12-20 | Arrow International, Inc. | $2,500 | Research payment | Cash or cash equivalent | GUIDELINER Device, INTERVENTIONAL ACCESS | "A Real World Multi-Center Retrospective Chart Review Study of GuideLiner Coast Catheters" | 2024 |
| 2024-12-20 | Novo Nordisk AS | $869 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Novo Nordisk AS | $778 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Recor Medical Inc | $260 | Research payment | Cash or cash equivalent | PARADISE RENAL DENERVATION SYSTEM Device, Nephrology | RADIANCE II | 2024 |
| 2024-12-19 | Genentech, Inc. | $60,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | Novartis Pharmaceuticals Corporation | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | Recor Medical Inc | $8,308 | Research payment | Cash or cash equivalent | PARADISE RENAL DENERVATION SYSTEM Device, Nephrology | US GPS | 2024 |
| 2024-12-19 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | Medical Device Business Services, Inc. | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | GE HEALTHCARE | $8,387 | Research payment | Cash or cash equivalent | DEFINE/DEVELOP LEARNING PLATFORM | 2024 | |
| 2024-12-18 | Becton, Dickinson and Company | $6,683 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $5,574 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $2,907 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $1,189 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $476 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | ARGENX US, INC. | $300 | Research payment | Cash or cash equivalent | VYVGART Drug, Immunology | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of | 2024 |
| 2024-12-18 | Becton, Dickinson and Company | $159 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $133 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Becton, Dickinson and Company | $18 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Life Technologies Corporation | $54,302 | Royalty or License (26 payments) | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Kowa Holdings America, Inc. | $9,260 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-17 | HARMONY BIOSCIENCES LLC | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WAKIX Drug, Narcoplepsy | 2024 | |
| 2024-12-17 | Boston Scientific Corporation | $3,684 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | VITALYST Early Feasibility Study | 2024 |
| 2024-12-17 | Boston Scientific Corporation | $2,254 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | RELIEF | 2024 |
| 2024-12-17 | Kowa Holdings America, Inc. | $1,099 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-16 | Teva Pharmaceuticals USA, Inc. | $29,326 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | Parallel-Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg quarterly) in Female Patients aged 18-4 | 2024 |
| 2024-12-16 | Edwards Lifesciences Corporation | $17,316 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-16 | SANOFI US SERVICES INC. | $13,848 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and T | 2024 | |
| 2024-12-16 | Smith+Nephew, Inc. | $4,332 | Research payment | Cash or cash equivalent | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2024 | |
| 2024-12-16 | Kowa Holdings America, Inc. | $2,881 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-13 | Genentech, Inc. | $25,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | Teleflex LLC | $8,580 | Research payment | Cash or cash equivalent | Barrigel Pivotal Trial | 2024 | |
| 2024-12-13 | Kowa Holdings America, Inc. | $7,889 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-13 | Kowa Holdings America, Inc. | $7,300 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-13 | Teleflex LLC | $6,144 | Research payment | Cash or cash equivalent | Barrigel Pivotal Trial | 2024 | |
| 2024-12-13 | VERTEX PHARMACEUTICALS INCORPORATED | $2,850 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine | 2024 | |
| 2024-12-13 | Kowa Holdings America, Inc. | $1,911 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-13 | Teleflex LLC | $1,900 | Research payment | Cash or cash equivalent | Barrigel Pivotal Trial | 2024 | |
| 2024-12-13 | Teleflex LLC | $1,170 | Research payment | Cash or cash equivalent | Barrigel Pivotal Trial | 2024 | |
| 2024-12-13 | Stryker Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SONOPET IQ Device, NEURO SPINE ENT | 2024 | |
| 2024-12-13 | Lexicon Pharmaceuticals, Inc. | $627 | Research payment | Cash or cash equivalent | LX9211 | 2024 | |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $591 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $218 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $37 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $28 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $26 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-12 | Edwards Lifesciences Corporation | $8,935 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $6,482 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-12 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-11 | Mallinckrodt Hospital Products Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2024 | |
| 2024-12-10 | Gilead Sciences, Inc. | $294,715 | Research payment | Cash or cash equivalent | Stigma among primary care providers: characterizing attitudes and behaviors in the care of people with chronic hepatitis | 2024 | |
| 2024-12-10 | Siemens Medical Solutions USA, Inc. | $52,953 | Research payment | Cash or cash equivalent | Varian Ethos Treatment Planning Device, Oncology | Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer with Urethral Sparing: A Prospective Trial Using | 2024 |
| 2024-12-10 | E.R. Squibb & Sons, L.L.C. | $45,374 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | Trends in Clinical Prescribing Patterns for Apixaban in Patients with Morbid Obesity and Chronic Kidney Disease | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $4,306 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2024 |
| 2024-12-10 | Kowa Holdings America, Inc. | $3,020 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-10 | Acessa Health Inc. | $2,827 | Research payment | Cash or cash equivalent | ACESSA PROVU SYSTEM Device, Surgical | TRUST USA CP-00-0025 | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $2,587 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-12-10 | Kowa Holdings America, Inc. | $596 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-10 | Kowa Holdings America, Inc. | $162 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-10 | Kowa Holdings America, Inc. | $99 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-09 | PFIZER INC. | $519,588 | Research payment | Cash or cash equivalent | A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF | 2024 | |
| 2024-12-09 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2024 |
| 2024-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | $46,448 | Research payment | Cash or cash equivalent | BI 1015550 - Ph3 Open Label Extension | 2024 | |
| 2024-12-06 | Blueprint Medicines Corporation | $17,300 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 | |
| 2024-12-06 | Medtronic, Inc. | $5,848 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-06 | Medtronic, Inc. | $2,450 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-06 | Medtronic, Inc. | $337 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-06 | Medtronic, Inc. | $119 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-05 | Alnylam Pharmaceuticals Inc. | $18,030 | Research payment | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | 2024 |
| 2024-12-05 | Boston Scientific Corporation | $1,875 | Consulting Fee | Cash or cash equivalent | Device, Clinical Trial Product_PI | 2024 | |
| 2024-12-05 | Alnylam Pharmaceuticals Inc. | $520 | Research payment | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | 2024 |
| 2024-12-05 | Kowa Holdings America, Inc. | $496 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-05 | Kowa Holdings America, Inc. | $342 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-05 | Alnylam Pharmaceuticals Inc. | $260 | Research payment | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | 2024 |
| 2024-12-04 | Kowa Holdings America, Inc. | $136,552 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-04 | Kowa Holdings America, Inc. | $34,344 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-04 | Kowa Holdings America, Inc. | $32,761 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-04 | Kowa Holdings America, Inc. | $4,104 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-04 | Kowa Holdings America, Inc. | $3,162 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-04 | Genentech, Inc. | $2,365 | Research payment | Cash or cash equivalent | RVT-3101-201 (TAHOE) | 2024 | |
| 2024-12-04 | Kowa Holdings America, Inc. | $680 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-03 | Amgen Inc. | $59,266 | Research payment | Cash or cash equivalent | Ph3 ASCVD Outcomes Trial | 2024 | |
| 2024-12-03 | Amgen Inc. | $1,080 | Research payment | In-kind items and services | RW Treatment Patterns; Healthcare Resource Utilization and Cost of SLE | 2024 | |
| 2024-12-03 | Indivior Inc. | $1,000 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS | 2024 |
| 2024-12-03 | Indivior Inc. | $1,000 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS | 2024 |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $95,281 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Kowa Holdings America, Inc. | $75,148 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $1,960 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Kowa Holdings America, Inc. | $750 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $486 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | ARGENX US, INC. | $1 | Research payment | Cash or cash equivalent | VYVGART Drug, Immunology | Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efg | 2024 |
| 2024-12-02 | ARGENX US, INC. | $0 | Research payment | Cash or cash equivalent | VYVGART Drug, Immunology | Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efg | 2024 |
| 2024-12-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-11-29 | BTG International Inc. | $21,157 | Research payment | Cash or cash equivalent | VORAXAZE Drug, Toxicity Antidote (Methotrexate Toxicity) | Rechallenge with Methotrexate after Administration of Glucarpidase for Methotrexate-Associated Acute Kidney Injury | 2024 |
| 2024-11-27 | Edwards Lifesciences Corporation | $4,549 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2024 | |
| 2024-11-27 | Ferring Pharmaceuticals AS | $675 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational | 2024 |
| 2024-11-26 | Amgen Inc. | $18,425 | Research payment | Cash or cash equivalent | TAVNEOS Drug, Inflammation | Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_168 | 2024 |
| 2024-11-26 | Kowa Holdings America, Inc. | $11,302 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-11-26 | Kowa Holdings America, Inc. | $10,474 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 | |
| 2024-11-26 | Kowa Holdings America, Inc. | $4,903 | Research payment | Cash or cash equivalent | BAWH_KSI | 2024 |
The latest 200 records of 1,871.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments